ClinicalTrials.gg
CompletedNCT05995444Updated Dec 21, 2023

A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects

A Phase 1 interventional study of Epetraborole and matching placebo and Epetraborole in Healthy Volunteers, sponsored by AN2 Therapeutics, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-21.

Sponsored by AN2 Therapeutics, Inc · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A single-center, 4-way crossover study to evaluate the effect of single therapeutic and supratherapeutic oral doses of epetraborole on the heart rate (HR) corrected QT interval (QTc) by assessing concentration-QT (C-QT) relationship using exposure-response modeling.

Read the detailed description

On Day 1 of each period, subjects will receive 1 of 4 treatments: a single therapeutic dose of epetraborole (Treatment A), a single supratherapeutic dose of epetraborole (Treatment B), a single dose of epetraborole-matching placebo (Treatment C), or a single dose of moxifloxacin (Treatment D). Cardiodynamic ECGs and PK blood samples for epetraborole, metabolite M3, and moxifloxacin (as applicable) will be collected predose and for 24 hours postdose in each period.

There will be a washout of at least 10 days between doses.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • QTc
  • Epetraborole
03

In context

Lead sponsor

AN2 Therapeutics, Inc is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Adult, male or female, 18-65 years of age, inclusive, at the screening visit.
  1. Subjects must agree to follow protocol-specified guidance
  2. Continuous non smoker for at least 3 months prior to the first dosing based on subject self-reporting
  3. (BMI) 18.0 and 32.0 kg/m2 at the screening visit.
  4. Medically healthy with no medical history, physical examination, laboratory profiles, and vital signs, as deemed by the Investigator or designee.
  5. No clinically significant history or presence of findings as judged by the Investigator or designee at the screening visit and first check-in

Exclusion criteria

Exclusion Criteria:

  1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  2. History or presence of medical or psychiatric condition or disease that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  3. Presence of bacterial infections requiring the use of antibiotic therapy within 3 months prior to the first dosing.
  4. History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.
  5. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months prior to the first dosing.
  6. History or presence of or idiosyncratic reaction to the study drugs or related compounds (e.g., fluoroquinolones, epetraborole ), or allergy to electrode adhesive patches or adhesive dressings/medical tape.
  7. History or presence of any of the following, deemed clinically significant by the Investigator or qualified designee:

    1. Ventricular pre-excitation syndrome (Wolff Parkinson White syndrome)
    2. Arrhythmia or history of arrhythmia requiring medical intervention
    3. Risk factors for TdP (e.g., heart failure, cardiomyopathy, family history of Long Syndrome, or sudden unexpected cardiac death at a young age)
    4. Sick sinus syndrome, second- or third-degree atrioventricular block, myocardial infarction, pulmonary congestion, symptomatic or significant cardiac arrhythmia, prolonged QTcF interval, or conduction abnormalities
  8. Is lactating or has a positive pregnancy test at the screening visit or first check-in (females only).
  9. Positive urine drug or alcohol results at the screening visit or first check-in.
  10. Positive results for (HIV), surface antigen (HBsAg), or virus (HCV) at the screening visit.
  11. Positive results for coronavirus disease 2019 (COVID-19) at first check-in.
  12. Unable to refrain from or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning

14 days prior to the first dosing.

  1. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing.
  1. Donation of blood or blood products or significant blood loss within 56 days prior to the first dosing or plans to donate blood products through the follow-up contact.
  1. Participation in another clinical study and received an agent within 30 days or within 5 half-lives (if known), prior to the first dosing, whichever is longer. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    500 mg epetraborole

    500 mg epetraborole

    Drug: Epetraborole

  • Experimental
    2000 mg epetraborole

    2000 mg epetraborole

    Drug: Epetraborole

  • Placebo comparator
    Epetraborole-matching placebo

    Epetraborole-matching placebo

    Drug: Epetraborole and matching placebo · Drug: Placebo

  • Active comparator
    400 mg moxifloxacin

    400 mg moxifloxacin

    Drug: Moxifloxacin

Interventions

  • DrugEpetraborole and matching placebo

    Treatment A (Therapeutic): 500 mg epetraborole (2 x 250 mg tablets) and epetraborole matching-placebo (6 tablets)

    Also known as: Therapeutic

  • Treatment B (Supratherapeutic): 2000 mg epetraborole (8 x 250 mg tablets)

    Also known as: Supratherapeutic

  • DrugPlacebo

    Treatment C (Placebo control): Epetraborole matching-placebo (8 tablets)

    Also known as: Placebo Control

  • Treatment D (Positive control): 400 mg moxifloxacin (1 x 400 mg tablet)

    Also known as: Positive Control

06

What researchers measure

Primary outcomes

  1. Changes to QTc interval

    Effect of epetraborole plasma concentrations on the QTc interval using linear mixed effect exposure-response modeling, including the predicted ddQTc at Cmax values corresponding to exposure levels of interest.

    Time frame: Study Day -1 to Study Day 2

Secondary outcomes

  1. Effect of epetraborole plasma concentrations on other ECG parameters on QTc

    Measure the Effect of epetraborole plasma concentrations on other ECG parameters on QTc

    Time frame: Study Day -1 to Study Day 2

  2. Assay sensitivity

    Assay sensitivity assessment with ddQTc at the geometric mean Cmax value predicted from a linear mixed effect model evaluating the relationship between QTc and moxifloxacin plasma concentrations (exposure-response modeling).

    Time frame: Study Day -1 to Study Day 2

  3. Analysis of dQTc

    QTc interval using a mixed effect analysis of covariance (ANCOVA) carried out as appropriate to analyze dQTc at each time point post baseline.

    Time frame: Study Day -1 to Study Day 2

  4. PK Concentration analysis for epetraborole and metabolite M3 of AUC0 t

    Analysis of PK Concentration for epetraborole and metabolite M3 of AUC0 t

    Time frame: Study Day -1 to Study Day 2

  5. Evaluation of TEAEs

    TEAEs

    Time frame: Study Day 1 through Study Day 14

  6. Safety Vital Signs changes of body temperature

    Measure Safety Vital Signs changes of body temperature

    Time frame: Study Day 1 through Study Day 14

  7. Orthostatic Vital Signs changes of Heart Rate from supine to standing position.

    Measure Orthostatic Vital Signs changes of Heart Rate from supine to standing position.

    Time frame: Study Day 1 through Study Day 14

  8. Effect of epetraborole plasma concentrations on other ECG parameters on, PR

    Measure the Effect of epetraborole plasma concentrations on other ECG parameters on, PR

    Time frame: Study Day -1 to Study Day 2

  9. Effect of epetraborole plasma concentrations on other ECG parameters on QRS duration

    Measure the Effect of epetraborole plasma concentrations on other ECG parameters on QRS duration.

    Time frame: Study Day -1 to Study Day 2

  10. Effect of epetraborole plasma concentrations on other ECG parameters on HR.

    Measure the Effect of epetraborole plasma concentrations on other ECG parameters on HR.

    Time frame: Study Day -1 to Study Day 2

  11. PK Concentration analysis for epetraborole and metabolite M3 of AUC0 inf

    Analysis of PK Concentration for epetraborole and metabolite M3 of AUC0 inf

    Time frame: Study Day -1 to Study Day 2

  12. PK Concentration analysis for epetraborole and metabolite M3 of AUC%extrap

    Analysis of PK Concentration for epetraborole and metabolite M3 of AUC%extrap

    Time frame: Study Day -1 to Study Day 2

  13. PK Concentration analysis for epetraborole and metabolite M3 of Cmax

    Analysis of PK Concentration for epetraborole and metabolite M3 of Cmax

    Time frame: Study Day -1 to Study Day 2

  14. PK Concentration analysis for epetraborole and metabolite M3 of Tmax

    Analysis of PK Concentration for epetraborole and metabolite M3 of Tmax

    Time frame: Study Day -1 to Study Day 2

  15. PK Concentration analysis for epetraborole and metabolite M3 of Kel

    Analysis of PK Concentration for epetraborole and metabolite M3 of Kel

    Time frame: Study Day -1 to Study Day 2

  16. PK Concentration analysis for epetraborole and metabolite M3 of t½

    Analysis of PK Concentration for epetraborole and metabolite M3 of t½

    Time frame: Study Day -1 to Study Day 2

  17. PK Concentration analysis for epetraborole and metabolite M3 of CL/F (parent only),

    Analysis of PK Concentration for epetraborole and metabolite M3 of CL/F (parent only),

    Time frame: Study Day -1 to Study Day 2

  18. PK Concentration analysis for epetraborole and metabolite M3 of Vz/F (parent only)

    Analysis of PK Concentration for epetraborole and metabolite M3 of Vz/F (parent only

    Time frame: Study Day -1 to Study Day 2

  19. PK Concentration analysis for epetraborole and metabolite M3 of MR AUC0 t

    Analysis of PK Concentration for epetraborole and metabolite M3 of MR AUC0 t

    Time frame: Study Day -1 to Study Day 2

  20. PK Concentration analysis for epetraborole and metabolite M3 of MR AUC0 inf

    Analysis of PK Concentration for epetraborole and metabolite M3 of MR AUC0 inf

    Time frame: Study Day -1 to Study Day 2

  21. PK Concentration analysis for epetraborole and metabolite M3 of MR Cmax

    Analysis of PK Concentration for epetraborole and metabolite M3 of MR Cmax

    Time frame: Study Day -1 to Study Day 2

  22. Safety Vital Signs changes of respiratory rate

    Measure Safety Vital Signs changes of respiratory rate

    Time frame: Study Day 1 through Study Day 14

  23. Safety Vital Signs changes of blood pressure

    Measure Safety Vital Signs changes of blood pressure (systolic and diastolic)

    Time frame: Study Day 1 through Study Day 14

  24. Safety Vital Signs changes of heart rate

    measure Safety Vital Signs changes of heart rate

    Time frame: Study Day 1 through Study Day 14

  25. Orthostatic Vital Signs changes of blood pressure from supine to standing position.

    Measure Orthostatic Vital Signs changes of blood pressure from supine to standing position (systolic and diastolic).

    Time frame: Study Day 1 through Study Day 14

07

Study locations

1 site
  • 423001
    Tempe, Arizona 85283, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jul 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Aug 16, 2023
StartActual
Jun 5, 2023
Primary completionActual
Jul 26, 2023
CompletionActual
Aug 3, 2023
Last update
Dec 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05995444
Lead sponsor
AN2 Therapeutics, Inc
Responsible party
Sponsor
First posted
Aug 16, 2023
Start date
Jun 5, 2023
Primary completion
Jul 26, 2023
Completion
Aug 3, 2023
Last update
Dec 21, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epetraborole

Start the discussion